Agent Capital

Portfolio Co Investors 2026 for Agent Capital: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Agent Capital accounts for 15 tracked companies with verified cap-table data, 15 of which disclose round sizes totalling $2.3B. The median disclosed raise is $154M, and the largest is Flare Therapeutics at $287M, ahead of Pliant Therapeutics ($251M) and Entrada Therapeutics ($241M).

The names that recur most often on these co-invested cap tables are Agent Capital (15 companies), Pfizer Ventures (6 companies), Alexandria Venture Investments (4 companies), Third Rock Ventures (3 companies), Invus (3 companies), Casdin Capital (3 companies). By latest disclosed round, the market skews Series B (6), Series A (4), Series C (2), IPO (2).

Best funded Agent Capital companies

  1. Flare Therapeutics — $287M (latest: Series C)
  2. Pliant Therapeutics — $251M (latest: IPO)
  3. Entrada Therapeutics — $241M (latest: Series A)
  4. Cerevance — $204M (latest: Series B)
  5. TRex Bio — $193M (latest: Series B)
  6. Initial Therapeutics — $187M (latest: IPO)
  7. Affini-T Therapeutics — $175M (latest: Seed)
  8. ImCheck Therapeutics — $154M (latest: Series B)
  9. Carisma Therapeutics — $120M (latest: Series B)
  10. Immunitas Therapeutics — $97M (latest: Series B)
  11. Foresight Diagnostics — $86M (latest: Series B)
  12. Mersana Therapeutics — $85M (latest: Series C)
  13. Interius BioTherapeutics — $76M (latest: Series A)
  14. DEM BioPharma — $70M (latest: Series A)
  15. Ä_x0081_shibio — $40M (latest: Series A)

Agent Capital Fund III GP, LLC — related firms and companies (56)

Agent Capital Fund III GP, LLC profile · All research reports